Literature DB >> 28554171

Clearance of Sclerostin, Osteocalcin, Fibroblast Growth Factor 23, and Osteoprotegerin by Dialysis.

Nicholas Carlson1, Ole H Mortensen, Mette Axelsen, Robert S Pedersen, James G Heaf.   

Abstract

INTRODUCTION: Fibroblast growth factor (FGF23), sclerostin, osteocalcin, and osteoprotegerin are important factors that control mineral bone metabolism. End-stage renal disease is associated with the pronounced dysregulation of mineral bone metabolism; however, the impact and clearance of mineral bone metabolism factors during dialysis remain largely undescribed.
METHODS: In a cross-sectional study, 10 chronic hemodialysis patients were treated with hemodialysis for 8 h using a high-flux filter and a dialysate bath of 50% calculated total body water continuously recycled at a rate of 500 mL/min. Plasma and dialysate concentrations of FGF23, sclerostin, osteoprotegerin, and osteocalcin were measured at 1, 2, 4, 6, and 8 h permitting the estimation of dialysis clearance.
RESULTS: Clearance of FGF23 was 7.7 mL/min, of sclerostin was 7.6 mL/min, of osteoprotegerin was 1.2 mL/min, and of osteocalcin was 19.7 mL/min. Clearance of FGF23 was correlated to sclerostin and osteoprotegerin clearance and also to the ultrafiltration rate. Although, osteocalcin blood concentrations decreased during dialysis, they rebounded within 6 h. Overall, no significant changes in blood concentrations of the measure mineral bone metabolism factors were observed.
CONCLUSIONS: The intradialytic clearance of osteocalcin, FGF23, sclerostin, and osteoprotegerin occurs; however, only clearance of FGF23 is directly correlated with the ultrafiltration rate. The effects of dialytic clearance on mineral bone metabolism are, however, uncertain and intradialytic plasma concentrations of the studied substrates remained largely unchanged.
© 2017 S. Karger AG, Basel.

Entities:  

Keywords:  Clearance; Dialysis; Fibroblast growth factor 23; Osteocalcin; Osteoprotegerin; Sclerostin

Mesh:

Substances:

Year:  2017        PMID: 28554171     DOI: 10.1159/000465513

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  5 in total

1.  Meta-analysis of the association between sclerostin level and adverse clinical outcomes in patients undergoing maintenance haemodialysis.

Authors:  Sha-Sha Li; Zhi-Qin Zhang; Da-Wei He; Ao-Lin He; Qi-Feng Liu
Journal:  Ther Adv Chronic Dis       Date:  2021-08-27       Impact factor: 5.091

2.  Hemodiafiltration Is Associated With Reduced Inflammation and Increased Bone Formation Compared With Conventional Hemodialysis in Children: The HDF, Hearts and Heights (3H) Study.

Authors:  Dagmar-Christiane Fischer; Colette Smith; Francesca De Zan; Justine Bacchetta; Sevcan A Bakkaloglu; Ayse Agbas; Ali Anarat; Bilal Aoun; Varvara Askiti; Karolis Azukaitis; Aysun Bayazit; Ipek Kaplan Bulut; Nur Canpolat; Dagmara Borzych-Dużałka; Ali Duzova; Sandra Habbig; Saoussen Krid; Christoph Licht; Mieczyslaw Litwin; Lukasz Obrycki; Fabio Paglialonga; Anja Rahn; Bruno Ranchin; Charlotte Samaille; Mohan Shenoy; Manish D Sinha; Brankica Spasojevic; Constantinos J Stefanidis; Enrico Vidal; Alev Yilmaz; Michel Fischbach; Franz Schaefer; Claus Peter Schmitt; Rukshana Shroff
Journal:  Kidney Int Rep       Date:  2021-07-06

Review 3.  The Emerging Role of Bone-Derived Hormones in Diabetes Mellitus and Diabetic Kidney Disease.

Authors:  Yixuan Li; Zuhua Gu; Jun Wang; Yangang Wang; Xian Chen; Bingzi Dong
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-11       Impact factor: 6.055

Review 4.  Cardiotoxicity of Uremic Toxins: A Driver of Cardiorenal Syndrome.

Authors:  Suree Lekawanvijit
Journal:  Toxins (Basel)       Date:  2018-09-01       Impact factor: 4.546

5.  The Impact of Sclerostin Levels on Long-Term Prognosis in Patients Undergoing Coronary Angiography: A Personalized Approach with 9-Year Follow-Up.

Authors:  Adam Kern; Tomasz Stompór; Jolanta Kiewisz; Bartłomiej E Kraziński; Jacek Kiezun; Marta Kiezun; Jerzy Górny; Ewa Sienkiewicz; Leszek Gromadziński; Dariusz Onichimowski; Jacek Bil
Journal:  J Pers Med       Date:  2021-03-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.